Primary objective:To establish the safety and toxicity profile of 166Ho-RE in patients with hepatocellular carcinoma. Secondary objectives:* To evaluate efficacy of 166Ho-RE in hepatocellular carcinoma without curative treatment options in a non-…
ID
Source
Brief title
Condition
- Hepatobiliary neoplasms malignant and unspecified
- Hepatobiliary neoplasms malignant and unspecified
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Safety, expressed as the rate of unacceptable toxicity.
Secondary outcome
* Tumor response.
* Changes in tumor marker alpha-fetoprotein.
* Quality of Life (QoL).
* Biodistribution / Dosimetry.
* Changes in hepatic function as determined by hepatobiliary scintigraphy.
Background summary
Patients with hepatocellular carcinoma often die from intrahepatic disease
since current treatment options are generally limited. Local treatment using
166Ho-radioembolization (166Ho-RE) could offer an effective treatment.
Study objective
Primary objective:
To establish the safety and toxicity profile of 166Ho-RE in patients with
hepatocellular carcinoma.
Secondary objectives:
* To evaluate efficacy of 166Ho-RE in hepatocellular carcinoma without curative
treatment options in a non-comparative phase II study.
* To evaluate tumor marker response.
* To evaluate Quality of Life (QoL).
* To evaluate biodistribution / dosimetry.
* To evaluate hepatic function.
Study design
Multi-center, interventional, treatment, non-randomized, open label,
non-comparative, early phase II study. The study is a collaboration between UMC
Utrecht and Erasmus MC Rotterdam. Recruitment and treatment of patients will
take place in both centers.
Intervention
166Ho-RE will be performed via a catheter during angiography.
Study burden and risks
It is anticipated that treatment with radioactive microspheres will reduce
tumor size and will improve quality of life. It is anticipated that the gamma
emission of the radioactive 166Ho will improve the safety of the procedure by
performing dose volume histogram analysis after scout dose imaging. Also the
differences in specific activity of 166Ho-microspheres and the dose rate
compared to the currently available 90Y-microspheres may theoretically improve
tumor response and accordingly, liver specific progression-free survival.
Participation in this study may also produce useful scientific data for the
future. Regular medical check-ups during the study can be seen as an additional
benefit. Scout dose and treatment procedures are scheduled on one day as
compared to two separate procedures in a standard 90Y-RE protocol.
Apart from the angiographic procedures and device related toxicity, standard
radiological and nuclear procedures are also used that may have their inherent
side effects (no extra visits). For the frequent blood sampling and/or pre- and
post-hydration, an indwelling cannula may be used and this may be accompanied
by mild bruising and also, in rare cases, by transient inflammation of the
vessel wall (phlebitis). The same applies to single vein punctures for blood
sampling. When needed, the use of a urethral catheter may also cause infection.
The total amount of blood withdrawn during the study will be up to 100 ml
(normal blood donation: 500 ml).
Heidelberglaan 100
Utrecht 3584 CX
NL
Heidelberglaan 100
Utrecht 3584 CX
NL
Listed location countries
Age
Inclusion criteria
- Patients must have given written informed consent.
- Female or male aged 18 years and over.
- Diagnosis of HCC established according to the Netherlands HCC guideline criteria (in line with American AASLD criteria): nodule >1 cm in a patient at risk for HCC, with combination of arterial hypervascularity and venous or delayed phase wash-out on multiphase CT-scan or MRI-scan. LR-5 and LR- 4 based on Liver Imaging Reporting and Data System (LIRADS) can be included based on discretion of the principal investigator.
- No curative treatment options (resection, transplant, or in case of solitary tumor <5 cm, RFA).
- Life expectancy of at least 6 months.
- ECOG Performance status 0-1.
- Liver-dominant disease (maximum 5 lung nodules all *1.0 cm and mesenteric or portal lymph nodes all *2.0 cm are accepted).
- Child-Pugh class A5-6 or B7.
- At least one measurable liver lesion according to the modified RECIST criteria.
- Negative pregnancy test for women of childbearing potential. Female patients of child-bearing potential should use an highly effective acceptable method of contraception (oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, intrauterine device or tubal ligation) or should be more than 1 year postmenopausal or surgically sterile during their participation in this study (from the time they sign the consent form), to prevent pregnancy.
Exclusion criteria
- Evidence of significant extrahepatic disease (MRI-scan liver and multiphase abdominal CT as well as a thoracic CT are routinely performed at screening).
- Radiation therapy within the last 4 weeks before the start of study therapy.
- Previous or current treatment with RE. Previous treatment with TACE, surgery, RFA, and previous or current treatment with sorafenib are allowed.
- Major surgery within 4 weeks or incompletely healed surgical incision before starting study therapy.
- Serum bilirubin >34.2 micromole/L (2 mg/dL).
- Glomerular filtration rate <35 ml/min, determined according to the Modification of Diet in Renal Disease (MDRD) formula.
- Non-correctable INR >1.5 in case of femoral approach (as opposed to radial).
- Leukocytes <2 109/l and/or platelet count <50 109/l.
- Significant cardiac event (e.g. myocardial infarction, superior vena cava (SVC) syndrome, New York Heart Association (NYHA) classification of heart disease *2 within 3 months before entry, or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia.
- Pregnancy or breastfeeding.
- Patients suffering from psychic disorders that make a comprehensive judgment impossible, such as psychosis, hallucinations and/or depression.
- Patients who are declared incapacitated.
- Previous enrollment in the present study.
- Male patients who are not surgically sterile or do not use an acceptable method of contraception during their participation in this study (from the time they sign the consent form) to prevent pregnancy in a partner.
- Evidence of untreated, clinically significant grade 3 portal hypertension (i.e. large varices at oesophago-gastro-duodenoscopy). In these cases, therapy with non-selective beta blocker (propranolol) or rubber band ligation should be instituted according to accepted guidelines. In case of small varices, prophylactic propranolol is advised.
- Portal vein thrombosis (tumor and/or bland) of the main branch (diagnosed on contrast enhanced transaxial images). Involvement of the right or left portal vein branches and more distal is accepted.
- Untreated active hepatitis. In case of detectable viral HBV load, treatment with a nucleos(t)ide analog such as entecavir or tenofovir should be instituted.
- Transjugular intrahepatic portosystemic shunt (TIPS).
- Body weight over 150 kg (because of maximum table load).
- Severe allergy for intravenous contrast used (Visipaque®)(because of CT evaluation, pre-treatment angiography and treatment angiography).
- Lung shunt >30 Gy, as calculated using scout dose SPECT/CT.
- Uncorrectable extrahepatic deposition of scout dose activity. Activity in the falciform ligament, portal lymph nodes and gallbladder is accepted.
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL52338.041.17 |